The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
Open accessAbstract
Despite standard-of-care treatment, more than 30% of patients with resectable colorectal cancer (CRC) relapse. Circulating tumor DNA (ctDNA) analysis may enable postsurgical risk stratification and adjuvant chemotherapy (ACT) treatment decision-making. We report results from GALAXY, which is an observational arm of the ongoing CIRCULATE-Japan study (UMIN000039205) that analyzed presurgical and postsurgical ctDNA in patients with stage II–IV resectable CRC ( n = 1,039). In this cohort, with a median follow-up of 16.74 months (range 0.49–24.83 months), postsurgical ctDNA positivity (at 4 weeks after surgery) was associated with higher recurrence risk (hazard ratio (HR) 10.0, P < 0.0001) and was the most significant prognostic factor associated with recurrence risk in patients with stage II or III CRC (HR 10.82, P < 0.001). Furthermore, postsurgical ctDNA positivity identified patients with stage II or III CRC who derived benefit from ACT (HR 6.59, P < 0.0001). The results of our study, a large and comprehensive prospective analysis of ctDNA in resectable CRC, support the use of ctDNA testing to identify patients who are at increased risk of recurrence and are likely to benefit from ACT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because KRAS mutations are often clonal founder events, mutant KRAS ctDNA can serve as a highly informative molecular marker for tumor burden, treatment response, minimal residual disease, and emergence of resistance [29,47,77,78].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Tie, J., Cohen, J. D., Lahouel, K., Lo, S. N., Wang, Y., Kosmider, S., Wong, R., Shapiro, J., Lee, M., Harris, S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200075 · Cited by 1,091
Kuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056
Reinert, T., Henriksen, T. V., Christensen, E., Sharma, S., Salari, R., Sethi, H., Knudsen, M., Nordentoft, I., Wu, H.-T., Tin, A. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0528 · Cited by 1,011
Self-citationEngstrom, P. F., Arnoletti, J. P., Benson, A. B., Chen, Y.-J., Choti, M. A., Cooper, H. S., Covey, A., Dilawari, R. A., Early, D. S., Enzinger, P. C., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0056 · Cited by 683
Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3616 · Cited by 668
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., et al. (2021) · Nature · doi:10.1038/s41586-021-03642-9 · Cited by 646
Self-citationPersonalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., Ali, S., Cleator, S., Kenny, L., Stebbing, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3663 · Cited by 510
Self-citationAdjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
O'Connor, E. S., Greenblatt, D. Y., LoConte, N. K., Gangnon, R. E., Liou, J.-I., Heise, C. P., & Smith, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3426 · Cited by 451
Wang, Y., Li, L., Cohen, J. D., Kinde, I., Ptak, J., Popoli, M., Schaefer, J., Silliman, N., Dobbyn, L., Tie, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0512 · Cited by 224
Research works printed but not linked: 1
- Gray, J. R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. 16, 1141–1154 (1998).
Cited by
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 672
ctDNA-based molecular residual disease and survival in resectable colorectal cancer
Nakamura, Y., Watanabe, J., Akazawa, N., Hirata, K., Kataoka, K., Yokota, M., Kato, K., Kotaka, M., Kagawa, Y., Yeh, K.-H., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03254-6 · Cited by 255
Self-citationPant, S., Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C. E., Leal, A. D., Chung, V., Basturk, O., VanWyk, H., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02760-3 · Cited by 267
Mechanisms of metastatic colorectal cancer
Cañellas-Socias, A., Sancho, E., & Batlle, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00934-z · Cited by 249
Practical recommendations for using ctDNA in clinical decision making
Cohen, S. A., Liu, M. C., & Aleshin, A. (2023) · Nature · doi:10.1038/s41586-023-06225-y · Cited by 171
Self-citation
Metadata
- Authors
- Kotani, D., Oki, E., Nakamura, Y., Yukami, H., Mishima, S., Bando, H., Shirasu, H., Yamazaki, K., Watanabe, J., Kotaka, M., Hirata, K., Akazawa, N., Kataoka, K., Sharma, S., Aushev, V. N., Aleshin, A., Misumi, T., Taniguchi, H., Takemasa, I., Kato, T., Mori, M., & Yoshino, T.
- Affiliations
- National Cancer Center Hospital East (JP)
- Kyushu University (JP)
- Osaka Medical and Pharmaceutical University (JP)
- Shizuoka Cancer Center (JP)
- Yokohama City University Medical Center (JP)
- Sano Hospital (JP)
- University of Occupational and Environmental Health Japan (JP)
- Sendai Medical Center (JP)
- Hyogo Medical University (JP)
- Natera (United States) (US)
- Aichi Cancer Center (JP)
- Sapporo Medical University (JP)
- Osaka National Hospital (JP)
- Tokai University (JP)
- Corresponding author
- Oki, Eiji
- ORCID
- Kotani, Daisuke
- Oki, Eiji
- Nakamura, Yoshiaki
- Yukami, Hiroki
- Mishima, Saori
- Bando, Hideaki
- Shirasu, Hiromichi
- Yamazaki, Kentaro
- Watanabe, Jun
- Kotaka, Masahito
- Hirata, Keiji
- Akazawa, Naoya
- Kataoka, Kozo
- Sharma, Shruti
- Aushev, Vasily N.
- Aleshin, Alexey
- Misumi, Toshihiro
- Taniguchi, Hiroya
- Takemasa, Ichiro
- Kato, Takeshi
- Mori, Masaki
- Yoshino, Takayuki
- Venue
- Nature Medicine
- Published
- 2023-01
- Volume
- 29
- Issue
- 1
- Pages
- 127-134
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC9873552
- OpenAlex
- W4316507345
- Cited by
- 526
- References
- 21
- Citations by year
- 2026: 130 · 2025: 161 · 2024: 167 · 2023: 67
- FWCI
- 64.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 15 d)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (19ck0106447h0002)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- colorectal cancer, circulating tumor DNA, liquid biopsy, adjuvant chemotherapy, molecular residual disease, cancer recurrence risk, risk stratification, stage II and III colorectal cancer, galaxies
- MeSH terms
- Humans, Japan, Neoplasm Recurrence, Local, Biomarkers, Tumor, Colorectal Neoplasms, Proportional Hazards Models, Chemotherapy, Adjuvant, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. https://app.cochat.ai/papers/10.1038/s41591-022-02115-4
- The paper
- Kotani, D., Oki, E., Nakamura, Y., Yukami, H., Mishima, S., Bando, H., Shirasu, H., Yamazaki, K., Watanabe, J., Kotaka, M., Hirata, K., Akazawa, N., Kataoka, K., Sharma, S., Aushev, V. N., Aleshin, A., Misumi, T., Taniguchi, H., Takemasa, I., . . . Yoshino, T. (2023). Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nature Medicine. https://doi.org/10.1038/s41591-022-02115-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.